 |
Linda H. Malkas, Ph.D.
Professor of Medicine, Surgery, Pharmacology, Medical and Molecular Genetics
Vera Bradley Chair of Oncology
Co-Leader Indiana University Simon Cancer Center Breast Cancer Program
Indiana University School of Medicine, Indianapolis, IN
 Dr. Malkas received an A.S. degree in Engineering, a B.S. in Chemistry and a Ph.M. and Ph.D. in Biochemistry from the City University of New York. She then was a postdoctoral fellow at the Worcester Foundation for Experimental Biology in Shrewsbury, Massachusetts. She subsequently joined the faculty of the University of Maryland School of Medicine as an Assistant Professor in 1990. During her tenure at Maryland she was the first to isolate and characterize a fully functional multiprotein complex from human cells that supports DNA replication in vitro. Dr. Malkas then demonstrated that the DNA replication apparatus of human breast cancer cells mediates an error-prone (mutagenic) DNA synthetic process. She was also able to correlate acquisition of a mutagenic DNA replication mechanism in breast cancer with a modification of a specific protein in the DNA synthetic apparatus. Dr. Malkas is evaluating this protein as a potential biomarker for breast cancer and as a target for cancer therapy. She attained the rank of Full Professor at the University of Maryland in July 2001. While at Maryland she was a member of the Cancer Center and served on its strategic planning committee and as Chair of its internal grant review committee. She also was a co-leader of the University of Maryland Women’s Health Research Group. In January 2002 she joined the faculty at the Indiana University School of Medicine as a Professor of Medicine, and was named the Vera Bradley Chair for Oncology. In March 2002 she was named the co-leader of the Indiana University Cancer Center’s Breast Cancer Program. Dr. Malkas’ research program has been funded since 1993 by awards from the National Institutes of Health (NIH)/National Cancer Institute. She has given a number of plenary and platform presentations at both National and International scientific meetings. In 2005 she co-founded a biotech company in Indianapolis, CS-Keys, Inc., that is translating the cancer-related diagnostic discoveries made in her laboratory to the medical community at large. In April 2010 she co-founded a new spin off company from CS-Keys, SynTherix, Inc., that is dedicated to the development of new cancer targeted therapeutics.
|
|
